4:06 PM
 | 
Oct 11, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA approves Roche's Hemlibra for hemophilia without inhibitors

FDA approved an sBLA for Hemlibra emicizumab-kxwh from Roche (SIX:ROG; OTCQX:RHHBY) to reduce the frequency of bleeding episodes in adults and children with hemophilia A without Factor VIII inhibitors. The company said it is now the only...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >